The Recall Desk
ModerateFDA (Drugs)·D-1340-2022·Announced 2022-07-27

FDA Recalls Launch Sequence Euphoria Capsules as Unapproved Drug

Launch Sequence Euphoria Capsules were marketed without FDA approval. Consumers should discontinue use immediately and contact the manufacturer.

What this means for you

Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.

Our severity reasoning: This is an FDA Class II recall of an unapproved drug product. No illnesses, injuries, or hospitalizations have been reported. The recall addresses a regulatory violation—marketing a drug without FDA approval—rather than a documented safety hazard.

Plain-English summary

Launch Sequence Euphoria Capsules, 10-count tins, are being recalled because they were marketed without an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) from the FDA. The product's label claims indicate it is a drug, but no FDA approval was obtained prior to distribution.

The recalled product was distributed nationwide in the USA and Canada. The affected lot number is C07172101, with an expiration date of July 2024. Consumers who have purchased the product should discontinue use immediately.

For additional information or to report adverse effects, consumers may contact the manufacturer, Loud Muscle Science.

The recalled product

Product
Launch Sequence Euphoria Capsules, 10- count tins, ASIN B08ZJX4V9J, UPC Code 661020846864.
Manufacturer
Loud Muscle Science
Category
Drug — Unapproved Drug
Hazard
  • unapproved-drug

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Lot# C07172101
  • Exp date: 07/2024.

Distribution

Distributed nationwide across the United States.

Related recalls

Same category